Remove Chronic Pain Remove Clinical Trials Remove Events Remove Safety
article thumbnail

Clinical Trial: Cannabinoid Administration Via a Metered-Dose Inhaler Is Safe and Effective for Chronic Pain Patients

NORML

The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain. The 1mg dose showed a significant pain decrease compared to the placebo.

article thumbnail

RYAH Medtech Inc. Completes Initial Shipment for Major UK-based Clinical Trial

Cannabis Law Report

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Study: Marijuana Inhaler Safe and Effective for Treating Chronic Pain

The Joint Blog

The study, titled Pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial , was first published by NORML. “The 1mg dose showed a significant pain decrease compared to the placebo. .

article thumbnail

Virpax Announces Clinical Trial Site in Canada for First in Human Study of Epoladerm™ for Pain Associated with Osteoarthritis of the Knee

Cannabis Law Report

(“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc.,

article thumbnail

Flora Growth Forms Flora Pharma Division, Launches Global Clinical Trials

Cannabis Law Report

(NASDAQ: FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is pleased to announce that it has signed an agreement to begin scientific clinical trials globally. Forward-looking statements are only predictions. Investor Relations: Evan Veryard.

article thumbnail

Study: Potential Adverse Drug Events When Combining THC with Other Medication

The Joint Blog

This study summarizes potential adverse drug events related to THC when combined with other medications Medicinal Use of Marijuana Cannabis has been used widely across North America in various state or provincial medical marijuana programs. However, in some cases, the risks may outweigh even the proven benefits.

Events 48
article thumbnail

Virpax Reports Successful Results of Toxicology and Pharmacokinetic Study for Epoladerm™

Cannabis Law Report

Charles River Laboratories, a renowned CRO engaged by Virpax to perform Food and Drug Administration (FDA) required pre-clinical studies, has completed a single dose pharmacokinetic study of dermal administration of Epoladerm in minipigs as part of the required Investigational New Drug Application (“IND”) enabling trials.